Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

Ähnliche Einträge

• Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer
  von: Abhishek G. Sathe, et al.
  Veröffentlicht: (2024)
• A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide
  von: Emmanuel Chigutsa, et al.
  Veröffentlicht: (2025)
• Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer
  von: Maddalena Centanni, et al.
  Veröffentlicht: (2025)
• Population Pharmacokinetic and Exposure–Response Modeling to Inform Risankizumab Dose Selection in Patients With Ulcerative Colitis
  von: Neha Thakre, et al.
  Veröffentlicht: (2024)
• Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates
  von: Andrew B. SyBing, et al.
  Veröffentlicht: (2025)